Filtrer vos résultats
- 2
- 1
- 2
- 1
- 3
- 1
- 1
- 1
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remissionAnnual European Congress of Rheumatology (EULAR), Jun 2019, Madrid, Spain. pp.715-716, ⟨10.1136/annrheumdis-2019-eular.5060⟩
Communication dans un congrès
hal-03606082v1
|
||
|
Lack of Association between the TNFAIP3 Rs2230926 Variant and Rheumatoid Arthritis-Associated Lymphoma.Joint Bone Spine, 2022, 89 (5), pp.105390. ⟨10.1016/j.jbspin.2022.105390⟩
Article dans une revue
hal-03792023v1
|
||
|
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM StudyRheumatology and Therapy, 2021, 8 (1), pp.95-108. ⟨10.1007/s40744-020-00253-0⟩
Article dans une revue
hal-03220867v1
|